The
eating disorders (DCA) are complex systemic diseases with high social impact, which tend to become chronic with significant medical and psychiatric comorbidities. The literature data showed that there is good evidence to suggest the use of
SSRIs, particularly at high doses of
fluoxetine, in the treatment of BN reducing both the crisis of binge that the phenomena compensates and reducing the episodes of binge in patients with BED in the short term. Also, the
topiramate (an AED) showed a good effectiveness in reducing the frequency and magnitude of episodes of binge with
body weight reduction, both in the BN that is in the
therapy of BED. To date, modest data support the use of low doses of second-generation
antipsychotics in an attempt to reduce the creation of polarized weight and body shapes, the obsessive component, and anxiety in patients with AN. Data in the literature on long-term
drug treatment of
eating disorders are still very modest. It is essential to remember that the
pharmacotherapy has, however, a remarkable efficacy in treating
psychiatric disorders that occur in comorbidity with
eating disorders, such as
mood disorders, anxiety,
insomnia, and
obsessive-compulsive personality disorders and behavior.